BridgeBio Pharma Inc. announced preliminary unaudited financial results for the fourth quarter and full year 2025, reporting net product revenue from Attruby (acoramidis) of $146.0 million for Q4 and $362.4 million for the full year. Attruby is becoming widely used as a first-choice therapy for newly diagnosed ATTR-CM patients, with 6,629 unique patient prescriptions written by 1,632 prescribers as of December 31, 2025. The company also announced the launch of a new TTR amyloid depleter antibody program aimed at exploring the potential reversal of ATTR-CM, with plans to advance into clinical trials between 2027 and 2028. In addition, interim analysis from the Phase 3 FORTIFY study of BBP-418 in LGMD2I/R9 showed a statistically significant 2.6-point benefit on the NSAD scale compared to placebo at 12 months. Based on these results, the FDA recommended that the company orient its NDA toward traditional full approval, with submission planned in the first half of 2026. BridgeBio also reported the identification of over 1,700 unique ADH1 patients since October 2023 and intends to submit an NDA for encaleret, based on Phase 3 CALIBRATE trial results, in the first half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623595-en) on January 12, 2026, and is solely responsible for the information contained therein.
Comments